Stroke Risk Reduction in Atrial Fibrillation Through Pharmacist Prescribing
JAMA Network Open · 24.07.2024 · 7 (7) · e2421993
DOI: 10.1001/jamanetworkopen.2024.21993 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 24.07.2024. Verfasst von Roopinder K Sandhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Pharmacists, Anticoagulants. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.
Themen: Schlaganfall
Abstract (Originalsprache)
Importance Major gaps in the delivery of appropriate oral anticoagulation therapy (OAC) exist, leaving a large proportion of persons with atrial fibrillation (AF) unnecessarily at risk for stroke and its sequalae.
Objective
To investigate whether pharmacist-led OAC prescription can increase the delivery of stroke risk reduction therapy in individuals with AF. Design, Setting, and Participants This prospective, open-label, patient-level randomized clinical trial of early vs delayed pharmacist intervention from January 1, 2019, to December 31, 2022, was performed in 27 community pharmacies in Alberta, Canada. Pharmacists identified patients 65 years or older with 1 additional stroke risk factor and known, untreated AF (OAC nonprescription or OAC suboptimal dosing) or performed screening using a 30-second single-lead electrocardiogram to detect previously unrecognized AF. Patients with undertreated or newly diagnosed AF eligible for OAC therapy were considered to have actionable AF. Data were analyzed from April 3 to November 30, 2023.
Interventions
In the early intervention group, pharmacists prescribed OAC using guideline-based algorithms with follow-up visits at 1 and 3 months. In the delayed intervention group, which served as the usual care control, the primary care physician (PCP) was sent a notification of actionable AF along with a medication list (both enhancement over usual care). After 3 months, patients without OAC optimization in the control group underwent delayed pharmacist intervention. Main Outcomes and Measures The primary outcome was the difference in the rate of guideline-concordant OAC use in the 2 groups at 3-month follow-up ascertained by a research pharmacist blinded to treatment allocation.
Results
Eighty patients were enrolled with actionable AF (9 [11.3%] newly diagnosed in 235 individuals screened). The mean (SD) age was 79.7 (7.4) years, and 45 patients (56.3%) were female. The median CHADS 2 (congestive heart failure, hypertension, age, diabetes, and stroke or transient ischemic attack) score was 2 (IQR, 2-3). Seventy patients completed follow-up. Guideline-concordant OAC use at 3 months occurred in 36 of 39 patients (92.3%) in the early intervention group vs 23 of 41 (56.1%) in the control group ( P < .001), with an absolute increase of 34% and number needed to treat of 3. Of the 23 patients who received appropriate OAC prescription in the control group, the PCP called the pharmacist for prescribing advice in 6 patients. Conclusions and Relevance This randomized clinical trial found that pharmacist OAC prescription is a potentially high-yield opportunity to effectively close gaps in the delivery of stroke risk reduction therapy for AF. Scalability and sustainability of pharmacist OAC prescription will require larger trials demonstrating effectiveness and safety. Trial Registration ClinicalTrials.gov Identifier: NCT03126214
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.
- Division of Cardiology, University of Alberta, Edmonton, Canada.
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
- Alberta Strategy for Patient-Oriented Research, University of Alberta, Edmonton, Canada.
- Alberta Health Services Provincial Research Data Services, Edmonton, Canada.
Förderung
- CIHR
Zitieren
APA
Sandhu, R. K., Fradette, M., Lin, M., Youngson, E., Lau, D., Bungard, T. J., Tsuyuki, R. T., Dolovich, L., Healey, J. S., & McAlister, F. A. (2024). Stroke Risk Reduction in Atrial Fibrillation Through Pharmacist Prescribing. JAMA Network Open, 7(7), e2421993. https://doi.org/10.1001/jamanetworkopen.2024.21993
Vancouver
Sandhu RK, Fradette M, Lin M, Youngson E, Lau D, Bungard TJ, et al. Stroke Risk Reduction in Atrial Fibrillation Through Pharmacist Prescribing. JAMA Network Open. 2024;7(7):e2421993. doi:10.1001/jamanetworkopen.2024.21993
BibTeX
@article{Sandhu2024,
author = {Sandhu, Roopinder K and Fradette, Miriam and Lin, Meng and Youngson, Erik and Lau, Darren and Bungard, Tammy J and Tsuyuki, Ross T and Dolovich, Lisa and Healey, Jeff S and McAlister, Finlay A},
title = {Stroke Risk Reduction in Atrial Fibrillation Through Pharmacist Prescribing},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {7},
pages = {e2421993},
doi = {10.1001/jamanetworkopen.2024.21993}
}
EUVIMED